Boardroom Alpha
Boardroom Alpha
TBI · Current Report (Form 8-K) · Filed February 3, 2026

Trueblue Inc — Current Report (Form 8-K)

Form
8-K
Filed
February 3, 2026
Period
Jan 30, 2026
Ticker
TBI
Accession
0000768899-26-000004
Boardroom Alpha · Filing insights

TrueBlue converts to asset-based revolving credit, reducing availability to $175M and retaining an option to expand by $150M.

About Trueblue Inc
Market cap
$205M
1Y TSR
−9.3%
3Y TSR
−30.8%
Board grade
D
Sector
Industrials
CEO
Taryn R Owen
Last annual meeting: May 11, 2026 · View full Trueblue Inc profile →
tbi-20260130

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 30, 2026
new trueblue logo GIF.gif
TrueBlue, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Washington
(State or Other Jurisdiction
of Incorporation)
001-14543 91-1287341
(Commission
File Number)
 (IRS Employer
Identification No.)
 
1015 A Street, Tacoma, Washington 98402
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:    (253) 383-9101

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueTBINew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).




Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 1.01.
Entry into a Material Definitive Agreement.
On January 30, 2026, TrueBlue, Inc. (the “Company”) entered into a Second Amendment to Amended and Restated Credit Agreement (the “Second Amendment”). The Agreement amends the Amended and Restated Credit Agreement entered into on February 9, 2024, as amended by the First Amendment to Amended and Restated Credit Agreement dated June 27, 2025, by and among the Company, as borrower, certain subsidiaries of the Company party thereto, as guarantors, Bank of America, N.A. as administrative agent, a lender, L/C issuer and swingline lender, and Wells Fargo Bank, N.A., PNC Bank, N.A., KeyBank, N.A., and HSBC Bank USA, N.A. as co-lenders (the “Agreement”).

The Second Amendment converts the Agreement from a cash-flow based revolving credit facility to an asset-based lending facility by replacing the existing structure of a revolving commitment with availability subject to satisfaction of certain financial maintenance covenants to a revolving commitment with availability subject to a borrowing base and a minimum excess availability covenant. The borrowing base is calculated as the sum of: (i) 90% of the value of Investment Grade Eligible Accounts (as defined in the Second Amendment), plus (ii) 85% of the value of Non-Investment Grade Eligible Accounts (as defined in the Second Amendment), plus (iii) 80% of the value of Eligible Unbilled Accounts (as defined in the Second Amendment), less specific availability reserves. The minimum excess availability covenant may subsequently be replaced with a springing fixed charge coverage ratio covenant upon the satisfaction of the Company’s meeting a minimum fixed charge coverage ratio test for two consecutive quarters occurring on or after September 27, 2026. Such fixed charge coverage ratio covenant will thereafter apply when Excess Availability (as defined in the Second Amendment) is below certain thresholds. The Amendment reduces the Company’s line of credit from $255 million to $175 million (as may be reduced by the borrowing base from time to time), while retaining the Company’s option to increase the amount by $150 million, subject to lender approval, with no changes in swingline sub-limits, letters of credit sub-limits, interest rate pricing or maturity date.

Under the pricing terms of the Agreement, which remain unchanged by the Second Amendment, the Company pays a variable rate of interest on the outstanding principal balance of loans under the Agreement, a fee on outstanding letters of credit and an unused commitment line fee. This rate is based on SOFR or the base rate (the highest of (x) the Bank of America prime rate, (y) the Federal Funds rate plus 0.50% and (z) SOFR plus 1.00%), plus an applicable spread which varies based on the Consolidated Leverage Ratio (as defined in the Second Amendment) of the Company. Letters of credit also include a fronting fee of 0.25%. Obligations under the Agreement, as amended by the Second Amendment, are secured by certain collateral of the Company and pledged equity of its material domestic subsidiaries. The Agreement contains customary representations and warranties, events of default, and affirmative and negative covenants.

This description of the Second Amendment does not purport to be complete, and is subject to and qualified in its entirety by reference to the full text of the Second Amendment, which is attached as Exhibit 10.1 to this Form 8-K, and is incorporated by reference herein.

Item 2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

To the extent required by Item 2.03 of Form 8-K, the information contained or incorporated in Item 1.01 of this Form 8-K with respect to the Second Amendment is incorporated by reference in this Item 2.03.

Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
Exhibit
Number
Exhibit DescriptionFiled Herewith
10.1X
104Cover page interactive data file - The cover page from this Current Report on Form 8-K is formatted as Inline XBRLX




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  TRUEBLUE, INC.
 (Registrant)
Date:February 3, 2026By:/s/ Todd N. Gilman
  Todd N. Gilman
  Senior Vice President, Deputy General Counsel, Corporate Secretary


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Trueblue Inc (TBI)

Reference

Frequently asked questions

When did Trueblue Inc file this 8-K?
Trueblue Inc (TBI) filed this Current Report (Form 8-K) with the SEC on February 3, 2026. The accession number assigned by EDGAR is 0000768899-26-000004.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
TrueBlue converts to asset-based revolving credit, reducing availability to $175M and retaining an option to expand by $150M. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Trueblue Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Trueblue Inc has filed under CIK 768899, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer